Shandong Pharmaceutical Glass Co.Ltd (SHA:600529)
China
· Delayed Price · Currency is CNY 19.63
-0.20 (-1.01%)
At close: Mar 9, 2026
SHA:600529 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 4,474 | 5,066 | 4,937 | 4,130 | 3,820 | Upgrade
|
| Other Revenue | - | 59.56 | 45.68 | 56.82 | 55.53 | Upgrade
|
| Revenue | 4,474 | 5,125 | 4,982 | 4,187 | 3,875 | Upgrade
|
| Revenue Growth (YoY) | -12.71% | 2.87% | 18.98% | 8.05% | 13.08% | Upgrade
|
| Cost of Revenue | 2,984 | 3,559 | 3,618 | 3,090 | 2,789 | Upgrade
|
| Gross Profit | 1,490 | 1,566 | 1,364 | 1,098 | 1,086 | Upgrade
|
| Selling, General & Admin | 340.09 | 341.62 | 332.17 | 251.59 | 230.19 | Upgrade
|
| Research & Development | 174.8 | 151.76 | 137.95 | 138.94 | 135.63 | Upgrade
|
| Other Operating Expenses | 28.88 | 39.06 | 33.84 | 32.03 | 31.19 | Upgrade
|
| Operating Expenses | 539.82 | 534.56 | 515.37 | 434.56 | 407.88 | Upgrade
|
| Operating Income | 950.46 | 1,031 | 848.58 | 662.95 | 678.38 | Upgrade
|
| Interest Expense | -0.51 | -0.03 | -0.23 | -0.26 | -0.28 | Upgrade
|
| Interest & Investment Income | 30.4 | 35.77 | 44.11 | 16.74 | 17.47 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 17.22 | 13.01 | 31.5 | -9.48 | Upgrade
|
| Other Non Operating Income (Expenses) | -3.22 | -2.36 | -2.8 | -0.2 | -2.44 | Upgrade
|
| EBT Excluding Unusual Items | 977.13 | 1,082 | 902.67 | 710.73 | 683.64 | Upgrade
|
| Gain (Loss) on Sale of Investments | 9.14 | 24.46 | 22.83 | 3.73 | 9.26 | Upgrade
|
| Gain (Loss) on Sale of Assets | 1.45 | -1.33 | -12.24 | -3.51 | -22.7 | Upgrade
|
| Asset Writedown | -156.89 | -5.09 | -12.88 | -16.96 | -11.61 | Upgrade
|
| Other Unusual Items | - | 10.74 | 10.44 | 14.06 | 30.13 | Upgrade
|
| Pretax Income | 830.83 | 1,111 | 910.82 | 708.05 | 688.72 | Upgrade
|
| Income Tax Expense | 141.2 | 167.81 | 135.02 | 89.76 | 97.63 | Upgrade
|
| Earnings From Continuing Operations | 689.63 | 942.99 | 775.8 | 618.29 | 591.09 | Upgrade
|
| Net Income | 689.63 | 942.99 | 775.8 | 618.29 | 591.09 | Upgrade
|
| Net Income to Common | 689.63 | 942.99 | 775.8 | 618.29 | 591.09 | Upgrade
|
| Net Income Growth | -26.87% | 21.55% | 25.48% | 4.60% | 4.72% | Upgrade
|
| Shares Outstanding (Basic) | 663 | 664 | 663 | 600 | 597 | Upgrade
|
| Shares Outstanding (Diluted) | 663 | 664 | 663 | 600 | 597 | Upgrade
|
| Shares Change (YoY) | -0.15% | 0.15% | 10.46% | 0.54% | 0.49% | Upgrade
|
| EPS (Basic) | 1.04 | 1.42 | 1.17 | 1.03 | 0.99 | Upgrade
|
| EPS (Diluted) | 1.04 | 1.42 | 1.17 | 1.03 | 0.99 | Upgrade
|
| EPS Growth | -26.76% | 21.37% | 13.59% | 4.04% | 4.21% | Upgrade
|
| Free Cash Flow | 345.06 | 517.27 | 376.45 | -458.27 | -58.82 | Upgrade
|
| Free Cash Flow Per Share | 0.52 | 0.78 | 0.57 | -0.76 | -0.10 | Upgrade
|
| Dividend Per Share | - | 0.620 | 0.400 | 0.300 | 0.300 | Upgrade
|
| Dividend Growth | - | 55.00% | 33.33% | - | - | Upgrade
|
| Gross Margin | 33.31% | 30.55% | 27.38% | 26.21% | 28.03% | Upgrade
|
| Operating Margin | 21.24% | 20.12% | 17.03% | 15.83% | 17.51% | Upgrade
|
| Profit Margin | 15.41% | 18.40% | 15.57% | 14.77% | 15.25% | Upgrade
|
| Free Cash Flow Margin | 7.71% | 10.09% | 7.56% | -10.94% | -1.52% | Upgrade
|
| EBITDA | 1,340 | 1,416 | 1,174 | 958.13 | 919.03 | Upgrade
|
| EBITDA Margin | 29.95% | 27.63% | 23.56% | 22.88% | 23.71% | Upgrade
|
| D&A For EBITDA | 389.67 | 384.77 | 325.13 | 295.17 | 240.64 | Upgrade
|
| EBIT | 950.46 | 1,031 | 848.58 | 662.95 | 678.38 | Upgrade
|
| EBIT Margin | 21.24% | 20.12% | 17.03% | 15.83% | 17.51% | Upgrade
|
| Effective Tax Rate | 16.99% | 15.11% | 14.82% | 12.68% | 14.17% | Upgrade
|
| Revenue as Reported | 4,474 | 5,125 | 4,982 | 4,187 | 3,875 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.